JCO-话题@MedSci

#JCO#

724篇内容 | 6844人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1891681, encodeId=4c1b1891681d8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：吉非替尼用于NSCLC术后辅助治疗，与化疗相比未改善OS（ADJUVANT-CTONG1104）, objectType=article, longId=215744, objectId=2724215e4404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2724215e4404, replyNumber=0, likeNumber=85, createdTime=2022-06-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2724215e4404, moduleTitle=JCO：吉非替尼用于NSCLC术后辅助治疗，与化疗相比未改善OS（ADJUVANT-CTONG1104）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2724215e4404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891675, encodeId=05f018916e5bc, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：rCOJEC，国际高危神经母细胞瘤患者的**诱导方案, objectType=article, longId=213060, objectId=099721306008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099721306008, replyNumber=0, likeNumber=86, createdTime=2021-07-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099721306008, moduleTitle=JCO：rCOJEC，国际高危神经母细胞瘤患者的**诱导方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099721306008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891684, encodeId=025a189168446, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：3期| 吉非替尼 vs 顺铂+长春瑞滨辅助治疗手术切除后的非小细胞肺癌的预后, objectType=article, longId=219788, objectId=61a2219e8811, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a2219e8811, replyNumber=0, likeNumber=91, createdTime=2022-06-23, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a2219e8811, moduleTitle=JCO：3期| 吉非替尼 vs 顺铂+长春瑞滨辅助治疗手术切除后的非小细胞肺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a2219e8811)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891666, encodeId=50491891666ff, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：两种辅助治疗方案用于I期HER2+乳腺癌患者的疗效对比, objectType=article, longId=212324, objectId=1b0521232415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b0521232415, replyNumber=0, likeNumber=87, createdTime=2021-07-28, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b0521232415, moduleTitle=JCO：两种辅助治疗方案用于I期HER2+乳腺癌患者的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b0521232415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891669, encodeId=d8961891669af, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：高复发/死亡风险的前列腺癌患者根治性切除术后或可采用辅助放疗巩固, objectType=article, longId=212448, objectId=76e9212448a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76e9212448a7, replyNumber=0, likeNumber=84, createdTime=2021-08-31, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76e9212448a7, moduleTitle=JCO：高复发/死亡风险的前列腺癌患者根治性切除术后或可采用辅助放疗巩固, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76e9212448a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891656, encodeId=36a9189165635, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, objectType=article, longId=211199, objectId=ffa121119985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa121119985, replyNumber=0, likeNumber=132, createdTime=2021-07-29, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa121119985, moduleTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffa121119985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891657, encodeId=d981189165e2f, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性, objectType=article, longId=211237, objectId=ce0a21123ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce0a21123ee7, replyNumber=0, likeNumber=67, createdTime=2022-01-12, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce0a21123ee7, moduleTitle=JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce0a21123ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891647, encodeId=a53f189164ef2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：超高分辨率配型对非亲缘供体造血细胞移植预后的影响, objectType=article, longId=209900, objectId=b649209900f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b649209900f8, replyNumber=0, likeNumber=91, createdTime=2021-06-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b649209900f8, moduleTitle=JCO：超高分辨率配型对非亲缘供体造血细胞移植预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b649209900f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891678, encodeId=6f7218916e85d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：梅奥建议，65 岁以上女性应进行遗传性癌症基因检测, objectType=article, longId=214796, objectId=c3de214e96d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3de214e96d7, replyNumber=0, likeNumber=89, createdTime=2022-02-25, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3de214e96d7, moduleTitle=JCO：梅奥建议，65 岁以上女性应进行遗传性癌症基因检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3de214e96d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891690, encodeId=ab30189169003, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险, objectType=article, longId=295266, objectId=a52729526605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a52729526605, replyNumber=0, likeNumber=79, createdTime=2022-11-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a52729526605, moduleTitle=JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a52729526605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891643, encodeId=def018916438a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：转移性非精原细胞性生殖细胞肿瘤患者的预后预测, objectType=article, longId=209700, objectId=78d4209e0067, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78d4209e0067, replyNumber=0, likeNumber=85, createdTime=2022-02-01, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78d4209e0067, moduleTitle=JCO：转移性非精原细胞性生殖细胞肿瘤患者的预后预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78d4209e0067)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891659, encodeId=cfe118916590e, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：早期定量PET-CT检查或可预测乳腺癌靶向治疗的反应性, objectType=article, longId=211553, objectId=5529211553ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5529211553ca, replyNumber=0, likeNumber=91, createdTime=2021-12-22, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5529211553ca, moduleTitle=JCO：早期定量PET-CT检查或可预测乳腺癌靶向治疗的反应性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5529211553ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891644, encodeId=4dab1891644a5, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：强化药物干预对采用新型口服抗癌药物治疗的安全性和患者报告的预后的影响, objectType=article, longId=209714, objectId=f1df209e14e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1df209e14e5, replyNumber=0, likeNumber=80, createdTime=2022-02-21, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1df209e14e5, moduleTitle=JCO：强化药物干预对采用新型口服抗癌药物治疗的安全性和患者报告的预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1df209e14e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891661, encodeId=2e71189166151, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：维奈托克联合FLAG-IDA可提高新确诊和复发/难治性AML的深度缓解率和移植成功率, objectType=article, longId=212161, objectId=e025212161ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e025212161ef, replyNumber=0, likeNumber=144, createdTime=2022-04-28, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e025212161ef, moduleTitle=JCO：维奈托克联合FLAG-IDA可提高新确诊和复发/难治性AML的深度缓解率和移植成功率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e025212161ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891667, encodeId=d441189166e1a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO:三阴乳腺癌（TNBC）患者新辅助化疗后残留，铂类化疗对比卡培他滨的疗效和安全性：随机III期研究（ECOG-ACRIN EA1131）, objectType=article, longId=212420, objectId=c51c2124203e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c51c2124203e, replyNumber=0, likeNumber=149, createdTime=2022-03-30, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c51c2124203e, moduleTitle=JCO:三阴乳腺癌（TNBC）患者新辅助化疗后残留，铂类化疗对比卡培他滨的疗效和安全性：随机III期研究（ECOG-ACRIN EA1131）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c51c2124203e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891664, encodeId=9c291891664e2, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：采用PET成像评估食管/食管胃交界癌早期治疗反应对患者预后的意义, objectType=article, longId=212269, objectId=66de212269fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66de212269fa, replyNumber=0, likeNumber=93, createdTime=2021-12-30, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66de212269fa, moduleTitle=JCO：采用PET成像评估食管/食管胃交界癌早期治疗反应对患者预后的意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66de212269fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891631, encodeId=31291891631f6, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, objectType=article, longId=207010, objectId=0c9920e0107e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c9920e0107e, replyNumber=0, likeNumber=95, createdTime=2021-08-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c9920e0107e, moduleTitle=JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c9920e0107e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891639, encodeId=738f189163946, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：纳武单抗联合伊匹单抗维持治疗晚期小细胞肺癌的疗效, objectType=article, longId=208997, objectId=017020899e31, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=017020899e31, replyNumber=0, likeNumber=220, createdTime=2022-01-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=017020899e31, moduleTitle=JCO：纳武单抗联合伊匹单抗维持治疗晚期小细胞肺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=017020899e31)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891679, encodeId=85fc18916e926, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：癌痛有多痛？50%的患者无法正常工作和生活, objectType=article, longId=214800, objectId=aafe214800de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafe214800de, replyNumber=0, likeNumber=79, createdTime=2021-10-21, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafe214800de, moduleTitle=JCO：癌痛有多痛？50%的患者无法正常工作和生活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafe214800de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891677, encodeId=573d18916e7b3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：横纹肌肉瘤的基因组特征及与临床预后的相关性, objectType=article, longId=213335, objectId=6b5c21333504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b5c21333504, replyNumber=0, likeNumber=100, createdTime=2022-05-19, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b5c21333504, moduleTitle=JCO：横纹肌肉瘤的基因组特征及与临床预后的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b5c21333504)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JCO

2020-05-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：吉非替尼用于NSCLC术后辅助治疗，与化疗相比未改善OS（ADJUVANT-CTONG1104）

2022-06-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：rCOJEC，国际高危神经母细胞瘤患者的**诱导方案

2021-07-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：3期| 吉非替尼 vs 顺铂+长春瑞滨辅助治疗手术切除后的非小细胞肺癌的预后

2022-06-23

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：两种辅助治疗方案用于I期HER2+乳腺癌患者的疗效对比

2021-07-28

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：高复发/死亡风险的前列腺癌患者根治性切除术后或可采用辅助放疗巩固

2021-08-31

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌

2021-07-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Lifileucel（一种基于肿瘤浸润性淋巴细胞的治疗）在转移性黑色素瘤的疗效和安全性

2022-01-12

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：超高分辨率配型对非亲缘供体造血细胞移植预后的影响

2021-06-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：梅奥建议，65 岁以上女性应进行遗传性癌症基因检测

2022-02-25

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：H1-抗组胺药可降低HBV、HCV或HBV-HCV合并感染患者患肝细胞癌的风险

2022-11-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：转移性非精原细胞性生殖细胞肿瘤患者的预后预测

2022-02-01

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：早期定量PET-CT检查或可预测乳腺癌靶向治疗的反应性

2021-12-22

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：强化药物干预对采用新型口服抗癌药物治疗的安全性和患者报告的预后的影响

2022-02-21

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：维奈托克联合FLAG-IDA可提高新确诊和复发/难治性AML的深度缓解率和移植成功率

2022-04-28

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO:三阴乳腺癌（TNBC）患者新辅助化疗后残留，铂类化疗对比卡培他滨的疗效和安全性：随机III期研究（ECOG-ACRIN EA1131）

2022-03-30

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：采用PET成像评估食管/食管胃交界癌早期治疗反应对患者预后的意义

2021-12-30

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Pegilodecakin+FOLFOX二线治疗未能改善吉西他滨难治性转移性胰腺癌的疗效

2021-08-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：纳武单抗联合伊匹单抗维持治疗晚期小细胞肺癌的疗效

2022-01-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：癌痛有多痛？50%的患者无法正常工作和生活

2021-10-21

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：横纹肌肉瘤的基因组特征及与临床预后的相关性

2022-05-19

科室
- - 订阅+
  - 更多科室
工具
服务